Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

New drug regimen is safe and effective in children with cystic fibrosis

An international, open-label Phase 3 study, co-led by Susanna McColley, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, found that a regimen of three drugs (elexacaftor/tezacaftor/ivacaftor) that targets the genetic cause of cystic fibrosis was safe and effective in 6-11-year-olds with at least one copy of F508del mutation in the CFTR gene, which is estimated to represent almost 90 percent of the cystic fibrosis population in the United States.

19 Mar 2021

A modified protein mediates development of lung fibrosis after cadmium/carbon black exposure

The triggers and causes of a severe scarring disease of the lungs -- idiopathic pulmonary fibrosis, or IPF -- remain unclear.

18 Mar 2021

Do Artemisia annua L. compounds have SARS-CoV-2 antiviral potential?

Caused by SARS-CoV-2, the ongoing COVID-19 pandemic has led to over 121.2 million cases and over 2.6 million deaths worldwide. An interesting new study examines the potential antiviral activity of compounds present in the plant Artemisia annua L.

18 Mar 2021

New approach may lead to novel treatments for renal fibrosis

Ageing is a common factor in many diseases. So, what if it were possible to treat them by acting on the causes of ageing or, more specifically, by acting on the shortening of telomeres, the structures that protect chromosomes?

16 Mar 2021

Cats with chronic kidney disease may help inform treatment for humans in future

The Wake Forest Institute for Regenerative Medicine is investigating how cats with chronic kidney disease could someday help inform treatment for humans.

13 Mar 2021

Novel CRISPR-based gene editor developed to correct mutations that cause genetic disorders

A team of researchers from the Agency for Science, Technology and Research's (A*STAR) Genome Institute of Singapore have developed a CRISPR-based gene editor, C-to-G Base Editor (CGBE), to correct mutations that cause genetic disorders.

11 Mar 2021

Researchers discover new molecular target that could treat idiopathic pulmonary fibrosis

Researchers at the University of Alabama at Birmingham have identified a new molecular target that could potentially treat the deadly, aging-related lung disease idiopathic pulmonary fibrosis (IPF).

10 Mar 2021

New high-performance, safe MRI contrast agent for 3D vascular mapping

Heart attack and stroke are the first and second leading causes of death in developed countries, respectively. As the disease often results in sudden death with few special prognostic symptoms, early diagnosis is very important.

10 Mar 2021

Simple blood test using nanoparticles could enable earlier detection of acute liver damage

University of Texas at Dallas chemist Dr. Jie Zheng has spent much of his career investigating gold nanoparticles for their potential impact in the field of nanomedicine.

10 Mar 2021

Organ-on-chip consortium receives huge grant to develop a universal standard for pharmaceutical industry

Scientists are pushing ahead building 'organ-on-chips', small chips with human cells, which are useful, for example, for studying cancerous metastases in the bloodstream or the development of scar tissue, or for testing the effect of drugs or food outside a human body.

10 Mar 2021

New study may lead to therapeutic strategies for chronic lung disease

Scientists at Washington University School of Medicine in St. Louis have implicated a type of immune cell in the development of chronic lung disease that sometimes is triggered following a respiratory viral infection.

10 Mar 2021

Ultrasound elastography do not show the actual status of postoperative liver fibrosis

It is well-known that patients who undergo Fontan surgery slowly develop liver fibrosis for years post-operatively. In the past decade, these incidences have been steadily increasing and this is due partly to the need for an accurate diagnostic method.

8 Mar 2021

IQWiG's new threshold proven feasible in practice for early benefit assessments of drugs

Current examples prove the feasibility of the 15 percent threshold newly defined by IQWiG for the acceptance of responder analyses in early benefit assessments of drugs.

5 Mar 2021

Study identifies potential therapeutic target for non-alcoholic fatty liver disease

An international team of researchers has identified the CNNM4 protein as a key regulator of magnesium in the liver and potential therapeutic target for non-alcoholic fatty liver disease, according to a study published in the Journal of Hepatology.

4 Mar 2021

Cell surface marker CD47 may allow early diagnosis of severe COVID-19

A new study reports the potential of the cell surface marker, CD47, as a biomarker for hyperinflammation, a characteristic feature of severe COVID-19.

4 Mar 2021

SARS-CoV-2 viremia predicts severe COVID-19 disease outcomes

The SARS-CoV-2 plasma viremia has been linked to severe disease and death in COVID-19 cases in small-scale cohort studies. The current study, published on the pre-print server medRxiv, aimed to study the mechanisms behind this relationship.

2 Mar 2021

New injectable hydrogel could heal cardiac tissue after heart attack

Researchers at CÚRAM, the SFI Research Centre for Medical Devices based at National University of Ireland Galway, and BIOFORGE Lab, at the University of Valladolid in Spain, have developed an injectable hydrogel that could help repair and prevent further damage to the heart muscle after a heart attack.

2 Mar 2021

Cellular maps capture COVID-19 pathogenesis in detail

Researchers in the United States and Finland have used tissues from people who died from coronavirus disease 2019 (COVID-19) to generate detailed cellular maps of the pathogenetic processes that occur within affected organs during severe disease.

1 Mar 2021

Bacteria use slimy strategy to defeat antibiotics that fight cystic fibrosis

University of Montana researchers and their partners have discovered a slimy strategy used by bacteria to defeat antibiotics and other drugs used to combat infections afflicting people with cystic fibrosis. The research was published Feb. 23 in the journal Cell Reports.

27 Feb 2021

Study on artificial microswimmers could improve the efficacy of targeted cancer therapy

A Mason Engineering researcher has discovered that artificial microswimmers accumulate where their speed is minimized, an idea that could have implications for improving the efficacy of targeted cancer therapy.

27 Feb 2021

Fibrosis News and Research

Further Reading

New drug regimen is safe and effective in children with cystic fibrosis

A modified protein mediates development of lung fibrosis after cadmium/carbon black exposure

Do Artemisia annua L. compounds have SARS-CoV-2 antiviral potential?

New approach may lead to novel treatments for renal fibrosis

Cats with chronic kidney disease may help inform treatment for humans in future

Novel CRISPR-based gene editor developed to correct mutations that cause genetic disorders

Researchers discover new molecular target that could treat idiopathic pulmonary fibrosis

New high-performance, safe MRI contrast agent for 3D vascular mapping

Simple blood test using nanoparticles could enable earlier detection of acute liver damage

Organ-on-chip consortium receives huge grant to develop a universal standard for pharmaceutical industry

New study may lead to therapeutic strategies for chronic lung disease

Ultrasound elastography do not show the actual status of postoperative liver fibrosis

IQWiG's new threshold proven feasible in practice for early benefit assessments of drugs

Study identifies potential therapeutic target for non-alcoholic fatty liver disease

Cell surface marker CD47 may allow early diagnosis of severe COVID-19

SARS-CoV-2 viremia predicts severe COVID-19 disease outcomes

New injectable hydrogel could heal cardiac tissue after heart attack

Cellular maps capture COVID-19 pathogenesis in detail

Bacteria use slimy strategy to defeat antibiotics that fight cystic fibrosis

Study on artificial microswimmers could improve the efficacy of targeted cancer therapy

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News